Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408914 · ClinicalTrials.gov registry record · Phase 2
Trial of High-Dose Rifampin in Patients With TB
A Phase 2 study, sponsored by Harvard University Faculty of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01408914 is a Phase 2 study that has completed, run by Harvard University Faculty of Medicine. The registered enrollment target is 180 participants.
The verdict
NCT01408914, a Phase 2 study, has completed, sponsored by Harvard University Faculty of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential of high doses of rifampin (RIF) to shorten treatment for tuberculosis (TB) without causing more adverse events. The hypotheses are that higher doses of RIF will result in higher blood concentrations of RIF; higher blood concentrations will result in tuberculosis bugs being killed more quickly; and, both of these will happen without more adverse events. Patients with active, infectious, drug-susceptible TB who agree to participate will be randomly assigned to 1 of 3 doses of RIF. All patients will also receive standard doses of regular (3) companion drugs for 2 months of daily, supervised therapy. The study will assess the following among the 3 study arms (oral doses of RIF 10, 15 \& 20 mg/kg/day) during the initial 8 weeks of treatment: 1) the amount of RIF in the blood after at least 14 days of treatment; 2) the difference in the number of tuberculosis bugs killed; 3) the frequency of adverse events.
Interventions
- DRUG Higher-Dose Rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408914
The ClinicalTrials.gov registry entry for NCT01408914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harvard University Faculty of Medicine, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Higher-Dose Rifampin is the first listed.
NCT01408914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408914 about?
NCT01408914 is a clinical study titled "Trial of High-Dose Rifampin in Patients With TB". The purpose of this study is to evaluate the potential of high doses of rifampin (RIF) to shorten treatment for tuberculosis (TB) without causing more adverse events. The hypotheses are that higher doses of RIF will result in higher blood concentrations of RIF; higher blood concentrations will resul...
What is the current status of trial NCT01408914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2013-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01408914?
The interventions under investigation include: Higher-Dose Rifampin (DRUG).
Who is sponsoring clinical trial NCT01408914?
This trial is sponsored by Harvard University Faculty of Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.